Healthcare / Medical DevicesNasdaqCM
$2.17
+0.03 (+1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.1M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-114.6%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-6.8M · FCF $-6.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | $249040.00 | — | — |
| Net Income | $-6.8M | $-6.8M | $-7.7M | $-10.0M | $-9.3M | $-3.5M | $-1.2M |
| EBITDA | $-6.7M | $-6.7M | $-6.7M | $-9.2M | $-9.0M | $-3.1M | $-1.0M |
| EPS | -15.25 | -15.25 | -456.75 | -12860.32 | -14733.67 | -13120.00 | — |
| Gross Margin | — | — | — | — | 19.6% | — | — |
| Operating Margin | — | — | — | — | -3741.5% | — | — |
| Net Margin | — | — | — | — | -3733.1% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.12 | 0.04 | — | — |
| Current Ratio | 2.81 | 2.81 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-6.2M | $-6.2M | $-8.1M | $-9.0M | $-8.9M | $-4.4M | — |
| Returns | |||||||
| ROE | -114.6% | -114.6% | -134.7% | -343.8% | -80.6% | -17.1% | 27.5% |
| Valuation | |||||||
| P/B | 0.16 | 0.16 | 0.14 | 0.51 | 0.91 | — | — |
| Growth & Yield | |||||||
| EPS Growth | 96.7% | 96.7% | 96.4% | 12.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-456.75 → -15.25
Residual
-65.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.